Case Report

Adalimumab-Induced Acute Myelogenic Leukemia

Authors: Nakhle S. Saba, MD, Semaan G. Kosseifi, MD, Edris A. Charaf, MD, Ahmad N. Hammad, MD


Newer biological treatment strategies have been developed in the last decade with some promising outcomes. Their safety, however, has been questioned lately with multiple reports of increased risk for malignancies and infectious complications. These reports render their use suboptimal. We report a 44-year-old woman receiving adalimumab (Humira®) for advanced juvenile rheumatoid arthritis who then developed acute myelogenic leukemia.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther 2005;5:1491–1504.
2. den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002;29:2288–2298.
3. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563–2571.
4. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–2285.
5. Ziakas PD, Giannouli S, Tzioufas AG, et al. Lymphoma development in a patient receiving anti-TNF therapy. Haematologica 2003;88:ECR25.
6. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006;5:228–231.
7. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151–3158.
8. Smith RE, Bryant J, DeCillis A, et al; National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195–1204.
9. Carli PM, Sgro C, Parchin-Geneste N, et al. Increase therapy-related leukemia secondary to breast cancer. Leukemia 2000;14:1014–1017.
10. Curtis RE, Boice JD Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745–1751.
11. Briasoulis E, Tzouvara E, Tsiara S, et al. Biphenotypic acute leukemia following intensive adjuvant chemotherapy for breast cancer: case report and review of the literature. Breast J 2003;9:241–245.
12. Ando M, Narabayashi M, Watanabe T, et al. Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines. Jpn J Clin Oncol 1999;29:28–32.
13. Chaplain G, Milan C, Sgro C, et al. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J Clin Oncol 2000;18:2836–2842.
14. Jang GD, Kim SW, Suh CW, et al. A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma. J Korean Med Sci 2002;17:555–559.
15. Ng A, Taylor GM, Eden OB. Treatment-related leukaemia—a clinical and scientific challenge. Cancer Treat Rev 2000;26:377–391.